KDM4B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2302798	0.51	5/20
SCHEMBL528024	0.47	5/20
SCHEMBL2187195	0.47	5/20
SCHEMBL2784506	0.47	5/20
SCHEMBL2121098	0.44	5/20
Thiocyanic Acid (SCHEMBL736619)	0.41	5/20
SCHEMBL663246	0.70	4/20
SCHEMBL1729498	0.69	4/20
SCHEMBL662995	0.66	4/20
SCHEMBL663937	0.66	4/20
SCHEMBL664672	0.66	4/20
SCHEMBL663231	0.64	4/20
SCHEMBL665201	0.64	4/20
SCHEMBL449879	0.63	4/20
SCHEMBL663017	0.63	4/20
SCHEMBL1728489	0.62	4/20
SCHEMBL664484	0.61	4/20
SCHEMBL1726833	0.60	4/20
SCHEMBL913277	0.58	4/20
SCHEMBL1621442	0.58	4/20

Clinical trials — most relevant to KDM4B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors	PHASE2	RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer	PHASE2	COMPLETED
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia	PHASE1	RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System	nan	UNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM4B binder may also engage these)

Protein	Name	Similarity
Q91VY5	—	1.000	Q91VY5 →
Q8VCD7	—	1.000	Q8VCD7 →
Q5RD88	—	0.999	Q5RD88 →
Q8BW72	—	0.999	Q8BW72 →
Q5TKR9	—	0.999	Q5TKR9 →
KDM4A	Lysine-specific demethylase 4A	0.996	landscape →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.996	landscape →
Q8BMD7	—	0.995	Q8BMD7 →
KDM4C	Lysine-specific demethylase 4C	0.995	landscape →
D3YWQ0	—	0.995	D3YWQ0 →
KDM4E	Lysine-specific demethylase 4E	0.995	landscape →
KDM5B	Lysine-specific demethylase 5B	0.995	landscape →
A0A1W2PPD8	—	0.995	A0A1W2PPD8 →
Q8BZ21	—	0.994	Q8BZ21 →
Q63553	—	0.994	Q63553 →
BRD1	Bromodomain-containing protein 1	0.994	landscape →
KAT8	Histone acetyltransferase KAT8	0.994	landscape →
KAT6B	Histone acetyltransferase KAT6B	0.994	landscape →
Q92539	—	0.994	Q92539 →
KDM2B	Lysine-specific demethylase 2B	0.994	landscape →
KDM5D	Lysine-specific demethylase 5D	0.993	landscape →
Q9UPV7	—	0.993	Q9UPV7 →
KDM4D	Lysine-specific demethylase 4D	0.993	landscape →
Q3U2K5	—	0.993	Q3U2K5 →
F1MAB7	—	0.993	F1MAB7 →
Q9V333	—	0.993	Q9V333 →
E1C2V1	—	0.993	E1C2V1 →
Q8WML3	—	0.993	Q8WML3 →
Q24K09	—	0.993	Q24K09 →
Q9V6L0	—	0.993	Q9V6L0 →